Drug CEO Targeted by Clinton Is Criticized by Drug Lobby

  • Turing "does not represent" values of drugmakers, group says
  • Drugmaker acquired old medicine, raised price 50-fold

Drug Goes From $13.50 to $750 Overnight

The top U.S. pharmaceutical lobby group said a drug company that has drawn criticism for a 50-fold price increase of a decades-old drug doesn’t match its companies’ values.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.